Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Depreciation & Amortization (CF) (2016 - 2025)

Theravance Biopharma (TBPH) has disclosed Depreciation & Amortization (CF) for 13 consecutive years, with $399000.0 as the latest value for Q4 2025.

  • Quarterly Depreciation & Amortization (CF) fell 5.45% to $399000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.6 million through Dec 2025, down 4.91% year-over-year, with the annual reading at $1.6 million for FY2025, 4.91% down from the prior year.
  • Depreciation & Amortization (CF) for Q4 2025 was $399000.0 at Theravance Biopharma, down from $405000.0 in the prior quarter.
  • The five-year high for Depreciation & Amortization (CF) was $1.6 million in Q3 2021, with the low at $251000.0 in Q4 2021.
  • Average Depreciation & Amortization (CF) over 5 years is $692750.0, with a median of $432000.0 recorded in 2023.
  • The sharpest move saw Depreciation & Amortization (CF) skyrocketed 162.55% in 2022, then tumbled 61.01% in 2023.
  • Over 5 years, Depreciation & Amortization (CF) stood at $251000.0 in 2021, then surged by 162.55% to $659000.0 in 2022, then crashed by 40.52% to $392000.0 in 2023, then grew by 7.65% to $422000.0 in 2024, then decreased by 5.45% to $399000.0 in 2025.
  • According to Business Quant data, Depreciation & Amortization (CF) over the past three periods came in at $399000.0, $405000.0, and $409000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.